A phase III clinical trial of JCAR017 in transplant-eligible second-line diffuse large B-cell lymphoma (DLBCL) patients
Phase of Trial: Phase III
Latest Information Update: 04 May 2018
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms TRANSCEND WORLD
- 04 May 2018 According to a Celgene Corporation media release, data from this study is expected to support international registration submissions for liso-cel in DLBCL.
- 04 May 2018 Status changed from planning to recruiting, according to a Celgene Corporation media release.
- 11 Jan 2018 New trial record